Sytrinol Clinical Trial Enters Phase III

Sytrinol Clinical Trial Enters Phase III

CHICAGOSourceOne GlobalPartners (www.source-1-global.com) announced the cardiovascular ingredientSytrinol will be the subject of a Phase III human clinical. The study is adouble blind, crossover, randomized trial of 120 moderately hypercholesterolemicmen and women who will consume 150 mg Sytrinol or placebo twice daily for 12weeks. The crossover element is the newest addition in this phase of theclinical work. The first two phases have shown beneficial results, includingcontinued cholesterol reductions over four, eight and 12 weeks.